Understanding the dose-response relationship of allopurinol: Predicting the optimal dosage

British Journal of Clinical Pharmacology

Volumn 76, Issue 6, 2013, Pages 932-938

  Graham, Garry G ^a,b   Kannangara, Diluk R W ^a,b   Stocker, Sophie L ^a,c   Portek, Ian ^d   Pile, Kevin D ^e   Indraratna, Praveen L ^a   Datta, Indira ^a   Williams, Kenneth M ^a,b   Day, Richard O ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ST GEORGE HOSPITAL   (Australia)

^e CAMPBELLTOWN HOSPITAL   (Australia)

Author keywords

allopurinol; creatinine clearance; gout; urate; uric acid

Indexed keywords

ALLOPURINOL; CREATININE; DIURETIC AGENT; OXIPURINOL; PROBENECID; URATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; FEMALE; HUMAN; KIDNEY FUNCTION; MALE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; URIC ACID BLOOD LEVEL;

ALLOPURINOL; CREATININE CLEARANCE; GOUT; URATE; URIC ACID;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; GOUT SUPPRESSANTS; HUMANS; LINEAR MODELS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; URIC ACID; YOUNG ADULT;

EID: 84888028037     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12126     Document Type: Article

References (34)

1. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM,. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 2007; 46: 623-644.
2. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I,. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324.
3. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R,. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012; 64: 1431-1446.
4. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G,. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology. 2007; 46: 1372-1374.
5. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N,. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461.
6. Hande KR, Noone RM, Stone WJ,. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47-56.
7. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R,. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001; 60: 981-983.
8. Panomvana D, Sripradit S, Angthararak S,. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. J Clin Rheumatol. 2008; 14: 6-11.
9. Dalbeth N, Kumar S, Stamp L, Gow P,. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006; 33: 1646-1650.
10. Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT,. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011; 63: 412-421.
11. Arellano F, Sacristan JA,. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27: 337-343.
12. Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N,. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012; 64: 2529-2536.
13. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT,. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102: 4134-4139.
14. Lee MH, Stocker SL, Anderson J, Phillips EJ, Nolan D, Williams KM, Graham GG, Sullivan JR, Day RO,. Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status? Intern Med J 2012; 42: 411-416.
15. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, Duruelo J, Alonso-Ruiz A,. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol. 1999; 5: 49-55.
16. Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT,. Furosemide increases plasma oxypurinol without lowering serum urate-a complex drug interaction: implications for clinical practice. Rheumatology. 2012; 51: 1670-1676.
17. Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO,. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol 2011; 38: 904-910.
18. Yue TF, Gutman AB,. Effect of allopurinol (4-hydroxypyrazolo-(3,4-D) pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 1964; 37: 885-898.
19. Rundles RW, Metz EN, Silberman HR,. Allopurinol in the treatment of gout. Ann Intern Med 1966; 64: 229-258.
20. Scott JT, Hall AP, Grahame R,. Allopurinol in treatment of gout. Br Med J 1966; 2: 321-327.
21. Elion GB, Yu TF, Gutman AB, Hitchings GH,. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 1968; 45: 69-77.
22. Rodnan GP, Robin JA, Tolchin SF, Elion GB,. Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA 1975; 231: 1143-1147.
23. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
24. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B,. Quantification of lean bodyweight Clin Pharmacokinet 2005; 44: 1051-1065.
25. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F,. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772.
26. R Core Team. R: A Language and Environment for Statistical Computing [Computer Program]. Vienna: R Foundation for Statistical Computing, 2012.
27. de Klerk E, van der Heijde D, Landewe R, van der Tempel H, Urquhart J, van der Linden S,. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003; 30: 44-54.
28. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW,. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006; 81: 925-934.
29. Solomon DH, Avorn J, Levin R, Brookhart MA,. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008; 67: 609-613.
30. Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS,. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009; 11: R46.
31. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M,. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004; 31: 1575-1581.
32. Stocker SL, McLachlan AJ, Savic RM, Kirkpatrick CM, Graham GG, Williams KM, Day RO,. The pharmacokinetics of oxypurinol in people with gout. Br J Clin Pharmacol 2012; 74: 477-489.
33. Garyfallos A, Magoula I, Tsapas G,. Evaluation of the renal mechanisms for urate homeostasis in uremic patients by the probenecid and pyrazinamide test. Nephron 1987; 46: 273-280.
34. Reese OG Jr, Steele TH,. Renal transport of urate during diuretic-induced hypouricemia. Am J Med 1976; 60: 973-979.